Chromatin Bioscience

Chromatin Bioscience

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Chromatin Bioscience leverages advanced bioinformatics and multi-omics analysis to decode 'genomic dark matter' and design novel, cell-selective synthetic promoters. The company operates as a B2B technology and services provider, offering custom promoter design to enhance gene expression control for partners in therapeutics, bioproduction, and agriculture. Its flexible business model includes technology access fees and milestone payments, with clients retaining ownership of the custom-designed IP.

Gene TherapyCell TherapyBiologics Production

Technology Platform

ChromatinLENS: A proprietary bioinformatics platform that analyzes multi-omics datasets to discover natural gene regulatory elements, enabling the design of custom, cell-type selective, and condition-responsive synthetic promoters and gene expression vectors.

Funding History

2
Total raised:$3.5M
Seed$3M
Grant$500K

Opportunities

Significant growth opportunities exist in securing partnerships with cell/gene therapy companies needing precise targeting, biomanufacturers seeking yield enhancement, and agribusiness firms developing next-generation crops.
The platform's applicability across diverse sectors provides multiple revenue streams and reduces dependency on any single market.

Risk Factors

Key risks include reliance on a business development-driven model with no guaranteed client pipeline, potential competition from larger synthetic biology firms, and the scientific risk that mined genomic elements may not function as predictably in novel synthetic contexts.
As a pre-revenue private company, access to capital is also a concern.

Competitive Landscape

Chromatin faces competition from synthetic biology service providers like Twist Bioscience and Ginkgo Bioworks, as well as therapeutic platform companies developing gene regulation tools. Its differentiation lies in its focus on epigenetic data mining to create novel, patentable, cell-selective promoters and a business model where clients retain the IP for custom designs.